Cite
HARVARD Citation
Zhuang, Z. et al. (n.d.). PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA. HemaSphere. pp. 1909-1910. [Online].